Search Results - "CONLEY, B. A"

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial by Mansfield, A. S., Wei, Z., Mehra, R., Shaw, A. T., Lieu, C. H., Forde, P. M., Drilon, A. E., Mitchell, E. P., Wright, J. J., Takebe, N., Sharon, E., Hovelson, D., Tomlins, S., Zeng, J., Poorman, K., Malik, N., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O’Dwyer, P. J., Chen, A. P., Flaherty, K. T.

“…The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-agnostic driver mutation-positive malignancies. Sub-protocols F and…”
Get full text

Analysis of Whole-Genome Sequences for the Prediction of Penicillin Resistance and β-Lactamase Activity in Bacillus anthracis by Gargis, A S, McLaughlin, H P, Conley, A B, Lascols, C, Michel, P A, Gee, J E, Marston, C K, Kolton, C B, Rodriguez-R, L M, Hoffmaster, A R, Weigel, L M, Sue, D

“…Penicillin (PEN) is a low-cost option for anthrax treatment, but naturally occurring resistance has been reported. β-Lactamase expression ( , ) in Bacillus…”
Get full text

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q by Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.

“…The National Cancer Institute—Molecular Analysis for Therapy Choice (NCI-MATCH) is a national precision medicine study incorporating centralized genomic…”
Get full text

Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors by CONLEY, B. A, EGORIN, M. J, TAIT, N, ROSEN, D. M, SAUSVILLE, E. A, DOVER, G, FRAM, R. J, VAN ECHO, D. A

“…Butyrates have been studied as cancer differentiation agents in vitro and as a treatment for hemoglobinopathies. Tributyrin, a triglyceride with butyrate…”
Get full text

NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss by Janku, F, Jegede, O, Puhalla, S L, Konstantinopoulos, P, Meric-Bernstam, F, Mitchell, E P, Zwiebel, J A, McShane, L M, Li, S, Rubinstein, L V, Doyle, L A, Patton, D, Conley, B A, O'Dwyer, P J, Harris, L N, Arteaga, C, Williams, P M, Hamilton, S R, Chen, A P, Flaherty, K T

Get full text

The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck by Suntharalingam, M, Haas, M L, Conley, B A, Egorin, M J, Levy, S, Sivasailam, S, Herman, J M, Jacobs, M C, Gray, W C, Ord, R A, Aisner, J A, Van Echo, D A

“…Unresectable squamous cell carcinomas of the head and neck (SCCHN) continue to pose a significant therapeutic challenge. This report defines the toxicities,…”
Get more information

Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics by CONLEY, B. A, EGORIN, M. J, SRIDHARA, R, FINLEY, R, HEMADY, R, WU, S, TAIT, N. S, VAN ECHO, D. A

“…A phase I trial of all-trans-retinoic acid (ATRA) was conducted to establish the maximum tolerable dose (MTD) of ATRA given once daily to patients with solid…”
Get full text

N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma by Sheikh, M S, Shao, Z M, Li, X S, Ordonez, J V, Conley, B A, Wu, S, Dawson, M I, Han, Q X, Chao, W R, Quick, T

“…Retinoid response pathways involve retinoic acid receptors (RARs) and retinoid X receptors. N-(4-hydroxyphenyl) retinamide (4-HPR), a derivative of…”
Get more information

Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids by Sheikh, M S, Shao, Z M, Li, X S, Dawson, M, Jetten, A M, Wu, S, Conley, B A, Garcia, M, Rochefort, H, Fontana, J A

“…Retinoids mediate their actions via RARs (retinoic acid receptors) and RXRs (retinoid X receptors). Each class of these nuclear retinoid receptors is further…”
Get full text

Pharmacodynamics in cancer therapy by Ratain, M J, Schilsky, R L, Conley, B A, Egorin, M J

“…Our understanding of anticancer pharmacodynamics, and the relationships between pharmacologic measurements and clinical effects, has grown markedly in recent…”
Get more information

Vascular Injury Induces Expression of Periostin: Implications for Vascular Cell Differentiation and Migration by Lindner, Volkhard, Wang, Qiaozeng, Conley, Barbara A, Friesel, Robert E, Vary, Calvin P.H

“…OBJECTIVE—Periostin mRNA is among the most strongly upregulated transcripts in rat carotid arteries after balloon injury. The goal of the present study was to…”
Get full text

Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice by CONLEY, B. A, RAMSLAND, T. S, SENTZ, D. L, SUHLAN WU, ROSEN, D. M, WOLLMAN, M, EISEMAN, J. L

“…The efficacy of 13-cis-retinoic acid (13-CRA) given as a single agent or in combination with tamoxifen (TAM) was determined in athymic nude mice bearing…”
Get full text

Current status of retinoids in chemoprevention of oral squamous cell carcinoma: an overview by Conley, B.A., Ord, R.A.

“…Squamous cell carcinoma of the oral cavity and oropharynx may be amenable to chemoprevention. This review focuses on current concepts of mechanisms in oral…”
Get full text

National Cancer Institute Clinical Trials Program in Colorectal Cancer by CONLEY, B. A, KAPLAN, R. S, ARBUCK, S. G

“…Colorectal cancer will be diagnosed in approximately 150,000 patients in the USA this year. Chemotherapy has recently been shown to improve survival when given…”
Get full text

Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques by Conley, Barbara A, Smith, Joshua D, Guerrero-Esteo, Mercedes, Bernabeu, Carmelo, Vary, Calvin P.H

“…Endoglin is a transmembrane protein that is found in association with transforming growth factor-beta (TGF-β) superfamily receptor complexes and has an…”
Get full text

An active, aldehydic metabolite of the cell-differentiating agent hexamethylene bisacetamide by Subramanyam, B, Callery, P S, Egorin, M J, Snyder, S W, Conley, B A

“…6-Acetamidohexanal has been identified in human plasma and urine as a metabolite of the cell-differentiating agent, hexamethylene bisacetamide (HMBA)…”
Get more information

Statistical and practical considerations for clinical evaluation of predictive biomarkers by Polley, Mei-Yin C, Freidlin, Boris, Korn, Edward L, Conley, Barbara A, Abrams, Jeffrey S, McShane, Lisa M

“…Predictive biomarkers to guide therapy for cancer patients are a cornerstone of precision medicine. Discussed herein are considerations regarding the design…”
Get full text

Genomically guided cancer treatments: from "promising" to "clinically useful" by Conley, Barbara A

Get full text

Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics by CONLEY, B. A, O'HARA, S, WU, S, MELINK, T. J, PARNES, H, PARDOE, E, EGORIN, M. J, VAN ECHO, D. A

“…To define a maximum tolerable dose, chloroquinoxaline sulfonamide (CQS) was given as a 1-h infusion every 28 days to cancer patients for whom no effective…”
Get full text

Approaches to optimal dosing of hexamethylene bisacetamide by CONLEY, B. A, EGORIN, M. J, SINIBALDI, V, SEWACK, G, KLOC, C, ROBERTS, L, ZUHOWSKI, E. G, FORREST, A, VAN ECHO, D. A

“…HMBA is a potent differentiating agent capable of causing > 95% morphological differentiation in cell lines in vitro. The induction of differentiation is…”
Get full text